All News
Ixekizumab COAST-V Trial Wins in Axial Spondyloarthritis
Lancet has published the results of a study showing that ixekizumab (an IL-17A inhibitor) yielded significant clinical benefit and radiographic protection when given to NSAID treated patients with radiographic axial spondyloarthritis (AxSpA).
Read ArticleDoubling Down on IL-17 In Psoriatic Arthritis
The monoclonal antibody bimekizumab, which neutralizes both interleukin (IL)-17A and 17F, was effective for both musculoskeletal and skin outcomes in psoriatic arthritis (PsA) in a phase IIb study.
Read ArticleSpotlight on Interstitial Lung Disease at ACR 2018
Here are a few important advances in our understanding of interstitial lung disease (ILD) from the ACR 2018 meeting last week.
Read ArticleAnti-phospholipid Antibodies and Myocardial Infarction.
The Annals of Internal Medicine features a communique from the Karolinska Institutet in Sweden demonstrating that elevated levels of antiphospholipid antibodies may be found in patients with myocardial infarction without any autoimmune co-morbidity, published in Annals of Internal M
Read ArticleTreat-to-Target Strategy Cuts Mortality in Gout Patients
More intense treatment of gout with a treat-to-target strategy can reduce patients' risk for death, a Spanish researcher told a press conference Monday at the American College of Rheumatology annual meeting here.
Read ArticleRheumNow ACR Week in Review: ACR Wrap-Up (10.26.18)
This past week in Chicago gave us a plethora of new and eye-opening research, people, KOLs, exhibits, sessions, guidelines, posters and a never-ending supply of coffee served in small paper cups. ACR 2018 highlights for me included:
Read ArticleWalking the Tightrope of Treat to Target in Psoriatic Arthritis
In the last few years, new studies have been published examining if early intervention and tight control (TC) of psoriatic arthritis (PsA) disease activity will have the same beneficial outcomes as it does for rheumatoid arthritis (RA).
Read ArticleNurse Led Gout Management Highly Effective
UK researchers have shown that nurse-led gout management, using a treat-to-target urate-lowering strategy, is efficacious and cost-effective compared with usual physicain care. The results are published in the recent Lancet edition.
Read ArticleIt's the Genes, Not the Diet that Raises Urate
Researchers from New Zealand find that in contrast with genetic contributions, diet explains very little variation in serum urate levels in the general population.
Read ArticleNEJM Debate on Medical Marijuana for Chronic Pain
This week’s NEJM features a case discussion and debate over whether medical marijuana should be used to treat chronic pain. The debate focuses on a 31-year-old woman with long-standing complex regional pain syndrome in her leg and foot.
Read ArticleApremilast Succeeds in Scalp Psoriasis
Celgene has announced results from the phase 3 STYLE study, showing apremilast yielding significant improvement in moderate-to-severe scalp psoriasis. STYLE is a phase 3, multicenter, randomized, placebo-controlled, double-blind study evaluating the efficacy and safety of apremilast in subjects with moderate to severe plaque psoriasis of the scalp. The study enrolled 303 people who were randomized 2:1 to receive apremilast 30 mg twice daily or placebo for the first 16 weeks.
Read ArticleTeenage Obesity Increases Lupus Risk
Analysis of the Black Women's Health Study shows that obesity as a teenager may be associated with increased risk of systemic lupus erythematous (SLE) in adulthood.
Read ArticlePhysical Therapy Equals Arthroscopic Surgery in Meniscal Tears
Several new trials suggest that conservative management may be as efficacious as arthroscopic surgery in patients with meniscal tears, thus contributing to the trend of fewer arthroscopic surgeries. A new trial of patients with nonobstructive meniscal tears shows no significant difference in 2 year outcomes between physical therapy and early arthroscopic partial meniscectomy.
Allopurinol Shown to be Renal Protective
Neogi and colleagues have shown that standard doses of allopurinol (300 mg/day) were associated with a 13% lower risk of renal function deterioration in chronic gout patients - thus, allopurinol does not appear to impair renal function over time.
Read ArticleAnxiety and Depression are Common in Arthritis Patients
The high prevalence of symptoms of anxiety and depression among adults with arthritis warrants awareness, screening, and subsequent treatment of these conditions.
Read ArticleVitamin D Fails to Improve Bone Health
The current edition of Lancet Diabetes & Endocrinology suggests that neither vitamin D supplementation, nor dose, will improve bone density or prevent fractures in adults.
Read ArticleActivity Trackers May be Helpful in Arthritis Patients
Use of wearable activity trackers was associated with increases in the number of daily steps among individuals with rheumatic and musculoskeletal disorders, a meta-analysis found.
Read ArticlePredictive Risk Factors for Uveitis in JIA
Researchers from Germany have studied a large cohort of juvenile idiopathic arthritis (JIA) patients and shown that JIA disease activity scores and laboratory biomarkers could be used to better define the group of JIA patients at high risk of uveitis onset.
Read ArticleZolendronic Acid Benefits Elder Women with Osteopenia
The NEJM reports that zolendronic acid was shown to significantly lower the risk of nonvertebral or vertebral fragility fractures in older women with osteopenia.
Read ArticleExcess Mortality in CTD or Systemic Vasculitis Patients
The Norwegian connective tissue disease (CTD) and systemic vasculitis (PSV) registry (NOSVAR) studied patient outcomes over a 15 year period and found overall mortality to be higher in the CTD compared to the PSV group.
Read Article


